| Range: | 6.5-21.66 | Vol Avg: | 325471 | Last Div: | 0 | Changes: | -0.34 |
| Beta: | 0.89 | Cap: | 0.22B | Currency: | USD | Exchange: | AMEX |
| Sector: | Healthcare | IPO: | Fri Sep 13 2019 | Empoloyees: | 50 | ||
| CUSIP: | 23256X100 | CIK: | 0001833141 | ISIN: | CA23256X1006 | Country: | CA |
| CEO: | Mr. Douglas L. Drysdale | Website: | https://www.cybin.com | ||||
CYBN 10.42 Stock Price Cybin Inc.
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow